The University College London Hospital (UCLH), University College London and the National Institute for Health Research UCLH Biomedical Research Centre have been collaborating with US diagnostics company Grail to sponsor the SUMMIT lung-cancer screening trial.
The study will enroll a total of 25,000 people from London and the surrounding areas aged between 55 and 77. Enrolment started in April 2019, and is expected to end in April 2021. Patients in the study undergo a lung health check, and if found to be eligible, are invited to the study. The study requires a blood sample and a low-dose computed tomography (CT) scan of their lungs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?